Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CANDEX vs AMPHOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Hypertension,Heart failure (NYHA class II-IV and left ventricular systolic dysfunction, to reduce cardiovascular mortality)
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
Adults: 150 mg orally once daily
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
99% bound to albumin (primarily), also to alpha-1-acid glycoprotein.
>95% bound to albumin and alpha-1-acid glycoprotein.
Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails.
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
Cr Cl 30-60 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 50 mg once daily; Cr Cl <15 m L/min: 50 mg every 48 hours
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
Not established for children <18 years of age
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
No specific adjustment required; consider renal function and potential for increased sensitivity
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
Fetal toxicity,Hypotension in volume-depleted patients,Renal function impairment,Hyperkalemia,Avoid concomitant use with aliskiren in patients with diabetes
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Hypersensitivity to candesartan or any component,Concomitant use with aliskiren in patients with diabetes,Pregnancy
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
Pharmacokinetic changes in pregnancy (increased volume of distribution, renal blood flow) may require dose adjustments. However, due to fetotoxicity, candesartan is contraindicated in pregnancy, and no dose recommendation is provided. Alternative antihypertensives such as labetalol or nifedipine are preferred.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Take exactly as prescribed, usually once daily.,Avoid potassium supplements or salt substitutes containing potassium without medical advice.,If you become pregnant, stop taking and contact your doctor immediately.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Report any signs of angioedema (swelling of face, lips, throat) or fainting.,Stay hydrated, especially if experiencing diarrhea or vomiting.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CANDEX vs AMPHOTEC, answered by our medical review team.
CANDEX is a Topical Antifungal and Corticosteroid that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.. AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CANDEX and AMPHOTEC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CANDEX is: Adults: 150 mg orally once daily. The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CANDEX and AMPHOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CANDEX is classified as Category C. Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malf. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.